RoosterBio Inc., a supplier of adult human mesenchymal stem/stromal cells (hMSCs), highly engineered media, and bioprocess development services, has partnered with Thermo Fisher Scientific to accelerate the availability of new, potentially life-saving cell and exosome therapies that have the potential to revolutionize the treatment of degenerative disease.

Uniting RoosterBio’s portfolio of hMSC-based products and processes with Thermo Fisher’s advanced therapy GMP contract manufacturing capabilities creates a new comprehensive solution for the development and manufacturing of hMSC and exosome therapeutics, accelerating timelines for production of clinical trial materials. Manufacturing services provided by Thermo Fisher will include upstream expansion of hMSCs, downstream purification of MSCs and MSC-derived exosomes, and drug product manufacturing.

“Thermo Fisher has an exceptional track record of success in the manufacture of clinical and commercial cell and gene therapies and a well-established global network to meet the needs of our customers,” said Tim Kelly, CEO of RoosterBio. “Biopharmaceutical companies striving to develop engineered cell and exosome therapies require proven, flexible technologies paired with reliable and scalable manufacturing capabilities. Through this collaboration, we will deliver that comprehensive solution to our customers, and I am delighted to work with Thermo Fisher to translate our MSC and exosome technologies into advanced therapy products for patients around the world.”

“Our collaboration with RoosterBio reflects our shared commitment to helping life-changing therapies reach patients in need, in the safest, fastest and most effective way possible,” added Ben Castro, Vice President and General Manager, Large Molecule, pharma services, Thermo Fisher. “We’re excited to work with the team to expand our Contract Development Manufacturing Organization (CDMO) services and support our biotechnology partners through the research and optimization, process development and manufacturing of critical treatments.”